Cardiovascular diseases articles within Nature Reviews Clinical Oncology

Featured

  • News & Views |

    Immune-checkpoint-inhibitor-associated myocarditis has a high fatality rate, warranting the development of more-effective treatment strategies. Herein, we discuss a recent report of a series of patients who were managed using a novel approach that involved personalized abatacept dosing, ruxolitinib and close respiratory monitoring, which was associated with low mortality.

    • Douglas B. Johnson
    •  & Alexander M. Menzies

  • Review Article |

    Use of radiotherapy or chemotherapy generally increases the survival of women with breast cancer; however, the use of radiotherapy, chemotherapy agents, such as the anthracycline doxorubicin, or anti-HER2 agents, such as trastuzumab, confer an increased risk of adverse cardiovascular events in these patients. In this Review, the authors describe the incidence and management of treatment-induced cardiac disease in women with breast cancer, and highlight strategies that might be used to minimize this risk.

    • Timothy M. Zagar
    • , Daniela M. Cardinale
    •  & Lawrence B. Marks

  • News & Views |

    Radiotherapy is known to cause heart disease. A recent analysis challenges several long-held tenets, indicating that radiation-induced cardiotoxicity might occur at lower doses, and earlier, than generally believed. We must be mindful of this toxicity and limit cardiac radiation dose as much as possible.

    • Timothy M. Zagar
    •  & Lawrence B. Marks

  • Review Article |

    Venous thromboembolism (VTE) is a potentially life-threatening condition that can be associated with significant morbidity and is linked to cancer by numerous pathophysiological mechanisms. Here, the risk factors, mechanisms, prevention, and optimal treatment of VTE in patients with cancer are discussed.

    • Annie Young
    • , Oliver Chapman
    •  & Ajay K. Kakkar

  • News & Views |

    The addition of hormonal therapy to radiation therapy improves survival in men with unfavorable risk prostate cancer. Yet, men with prostate cancer have higher rates of non-cancer death than the general population and most will die from causes other than their index malignancy. Co-morbid cardiovascular disease is strongly associated with cause of death and this raises the possibility that prostate cancer or its treatment increases cardiovascular disease risk and possibly mortality.

    • Jason A. Efstathiou
    • , William U. Shipley
    •  & Matthew R. Smith

Browse broader subjects

Browse narrower subjects

Browse Cardiovascular diseases across other nature.com journals